Omali Pitiyarachchi, Medical oncologist at the Lost Cancer Research Centre at UNSW Sydney, shared a post on X:
“Last session of ASCOBT26.
Had to stay to hear Molly Li’s talk. Cost of running a clinical trial in China is 50% less than in US or Europe! Advancements in tech platforms and AI driven drug dev’t have pushed the market exponentially -time for greater APAC collaboration?”
Other articles about ASCOBT26 on OncoDaily.
